scispace - formally typeset
J

Jianping Liu

Researcher at China Pharmaceutical University

Publications -  125
Citations -  2640

Jianping Liu is an academic researcher from China Pharmaceutical University. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 24, co-authored 99 publications receiving 1975 citations.

Papers
More filters
Journal Article

Stealth tanshinone IIA-loaded solid lipid nanoparticles: effects of poloxamer 188 coating on in vitro phagocytosis and in vivo pharmacokinetics in rats.

TL;DR: Phagocytosis studies showed significant differences between TA-SSLNs and TA-NSLNs and demonstrated that the poloxamer 188 coating could decrease the macrophage uptake and AUC of tanshinone IIA increased as a function of SLNs.
Journal ArticleDOI

Fabrication of TPGS-Stabilized Liposome-PLGA Hybrid Nanoparticle Via a New Modified Nanoprecipitation Approach: In Vitro and In Vivo Evaluation

TL;DR: Findings suggest the modified nanoprecipitation method holds great potential for fabricating LPN, aided by the multiple functions of TPGS, and the prepared TLPN is a promising delivery system for use in the pharmaceutical field.
Journal ArticleDOI

A novel modified paclitaxel-loaded discoidal recombinant high-density lipoproteins: Preparation, characterizations and in vivo evaluation

TL;DR: It is demonstrated that cP-d-rHDLs, whose remodeling behaviors were restrained effectively after structural modification, exhibited more excellent and promising properties as novel delivery vehicles for anti-cancer agents.
Journal ArticleDOI

Physicochemical characterization of asulacrine towards the development of an anticancer liposomal formulation via active drug loading: Stability, solubility, lipophilicity and ionization

TL;DR: The obtained physicochemical parameters provided insightful information useful to maximise DL into the liposomes, and explain a tendency of drug precipitation of pH-solubilized formulations following intravenous infusion.
Journal ArticleDOI

Evaluation of pharmacokinetic and pharmacodynamic relationship for oral sustained-release atenolol pellets in rats.

TL;DR: The more favorable characteristics of SRPs would make it more appropriate as a potential dosage form for the treatment of hypertension.